# PBS Transparency and Efficiencies Subgroup26 April 2018Communique

The PBS Listing Transparency and Efficiencies Subgroup met in Canberra on 24 April 2018. Attendees included representatives from Medicines Australia, the Generic and Biosimilar Medicines Association, and the Department of Health.

Members were provided with an update on the Streamlining Pathways project and agreed that this subgroup would also be consulted on proposals to revise the cost recovery arrangements in line with the Australian Government’s Cost Recovery Guidelines and any changes that may arise from streamlining processes.

## Cost Recovery

Members of the PBS Transparency and Efficiencies Subgroup will be consulted on revised cost recovery proposals to better reflect the real costs of activity associated with PBS processes, consistent with the Australian Government Cost Recovery Guidelines. Any proposed changes to improve the timeliness, transparency and efficiency of PBS processes will need to include revised cost recovery arrangements.

The Department walked members of Medicines Australia, the Generic and Biosimilar Medicines Association through the 2017-18 CRIS that had flagged proposals for changes to cost recovery would be taken to industry in 2018.

The group agreed to discuss the draft 2018-19 CRIS at a future meeting. It was noted that this CRIS would include the standard annual legislated increase to cost recovery charges prescribed by *National Health (Pharmaceutical and Vaccines – Cost Recovery) Regulations* 2009 based on the Consumer Price Index (CPI) and will be published on the PBS website in the coming months. This CRIS is machinery in nature and will not alter the cost recovery arrangements that have been in place since 1 January 2010.

In line with consultation forums in February 2018, it was noted that there has been no decision by the Australian Government to implement any changes to PBS cost recovery at this stage (other than legislative annual CPI changes).